Baidu
map

J Allergy Clin Immunol:哮喘或能增加带状疱疹发病的风险水平!

2015-12-29 chenshuo译 MedSci原创

http://www.medicalnewstoday.com/articles/304551.php

近日,一项最新的研究成果表明,哮喘可能会增加带状疱疹疾病的风险水平。


目前,在美国估计每年有100万人患有带状疱疹。尽管该疾病的常见发病人群为年龄在50-59岁的患者,即使刻意去预防该疾病,仍然会有相当一部分的人群无法避免发病,至于原因目前尚未明确。

而哮喘在日常生活中是一种常见的疾病,它是由气道长期炎症和狭窄,从而引起患者出现喘息、咳嗽、胸闷和呼吸困难等临床症状。

哮喘是当今美国五大慢性疾病之一,影响了2500万多个美国人,其中包括700万名儿童。

2013年时,罗切斯特梅奥诊所的研究人员曾针对以往建立在人群为基础的数据进行研究调查,结果发现患有哮喘的儿童发生带状疱疹的风险水平更高。

该研究的主导者Young Juhn 博士(儿科医生和哮喘流行病学梅奥实验室负责人)说:“哮喘对于感染或免疫功能紊乱的影响作用可能会远远超过对呼吸道的影响。”

在他们的研究中,梅奥小组审查了一直以来生活在奥姆斯特德县的50岁及以上年龄的成年人医疗记录。该研究团队比较了371例患有哮喘病患者和742例没有患者哮喘病的人发生带状疱疹的频率。

结果发现,371名哮喘患者中有87名(23%)发生带状疱疹,而另外一小组742人有114人(15%)发生带状疱疹。

该研究采用的统计方法称为Logistic回归分析,研究人员计算出成人哮喘患者出现带状疱疹的风险高达70%,相对于那些无患有哮喘的人群。

此外,他们还发现特应性皮炎和较高的带状疱疹风险之间的联系,在特应性皮炎患者实验组和对照组发生带状疱疹的几率分别为12%和8%。

虽然给团队没有进一步地探讨哮喘或皮炎与带状疱疹发生机制的具体环节,但在该研究中的结果明显说明了皮肤或呼吸道免疫功能受损的确与带状疱疹存在一定的联系。

居于研究的结果,该研究团队怀疑,也许可能是因为哮喘抑制了免疫系统的功能,从而激活了水痘-带状疱疹病毒发病的风险水平。

最后,Young Juhn博士总结道:

“对于哮喘,我们目前尚无法确切指出其为成年人带状疱疹病毒发病的主要风险因素之一,但是,我们可以考虑将50岁及以上年龄的患有哮喘或特应性皮炎的成年人作为目标群体进行带状疱疹疫苗免疫预防。”

原始出处:

Asthma linked to increased risk of shingles MNT 29 Dec 2015

Hyo Jin Kwon et al. Agnieszka Jozwik et al.,Asthma as a risk factor for zoster in adults: A population-based case-control study,  The Journal of Allergy and Clinical Immunology  28 December 2015



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2034469, encodeId=28ac2034469ac, content=<a href='/topic/show?id=bc6010088e05' target=_blank style='color:#2F92EE;'>#风险水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100887, encryptionId=bc6010088e05, topicName=风险水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sun May 01 23:37:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54670, encodeId=aaee546e089, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328884, encodeId=de68132888467, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 31 11:37:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580358, encodeId=fe7d158035869, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Dec 31 11:37:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50512, encodeId=fb8d5051294, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Wed Dec 30 14:06:00 CST 2015, time=2015-12-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2034469, encodeId=28ac2034469ac, content=<a href='/topic/show?id=bc6010088e05' target=_blank style='color:#2F92EE;'>#风险水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100887, encryptionId=bc6010088e05, topicName=风险水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sun May 01 23:37:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54670, encodeId=aaee546e089, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328884, encodeId=de68132888467, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 31 11:37:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580358, encodeId=fe7d158035869, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Dec 31 11:37:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50512, encodeId=fb8d5051294, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Wed Dec 30 14:06:00 CST 2015, time=2015-12-30, status=1, ipAttribution=)]
    2016-01-08 andruhn

    好东西,值得分享,学习了!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2034469, encodeId=28ac2034469ac, content=<a href='/topic/show?id=bc6010088e05' target=_blank style='color:#2F92EE;'>#风险水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100887, encryptionId=bc6010088e05, topicName=风险水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sun May 01 23:37:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54670, encodeId=aaee546e089, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328884, encodeId=de68132888467, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 31 11:37:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580358, encodeId=fe7d158035869, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Dec 31 11:37:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50512, encodeId=fb8d5051294, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Wed Dec 30 14:06:00 CST 2015, time=2015-12-30, status=1, ipAttribution=)]
    2015-12-31 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=2034469, encodeId=28ac2034469ac, content=<a href='/topic/show?id=bc6010088e05' target=_blank style='color:#2F92EE;'>#风险水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100887, encryptionId=bc6010088e05, topicName=风险水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sun May 01 23:37:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54670, encodeId=aaee546e089, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328884, encodeId=de68132888467, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 31 11:37:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580358, encodeId=fe7d158035869, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Dec 31 11:37:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50512, encodeId=fb8d5051294, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Wed Dec 30 14:06:00 CST 2015, time=2015-12-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2034469, encodeId=28ac2034469ac, content=<a href='/topic/show?id=bc6010088e05' target=_blank style='color:#2F92EE;'>#风险水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100887, encryptionId=bc6010088e05, topicName=风险水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Sun May 01 23:37:00 CST 2016, time=2016-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54670, encodeId=aaee546e089, content=好东西,值得分享,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328884, encodeId=de68132888467, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 31 11:37:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580358, encodeId=fe7d158035869, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Dec 31 11:37:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50512, encodeId=fb8d5051294, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Wed Dec 30 14:06:00 CST 2015, time=2015-12-30, status=1, ipAttribution=)]
    2015-12-30 lu2996

    学习中

    0

相关资讯

Respirology:哮喘不一定是过敏性疾病

已有研究表明,中性粒细胞炎症会导致成年人非嗜酸细胞性哮喘(NEA),但是目前关于儿童或青少年NEA的研究鲜有,因此研究者对青少年哮喘患者进行了一项研究,探究NEA的临床和炎症特点。该研究纳入了77名哮喘青少年患者以及68名没有哮喘的青少年(12-17岁),评估参与者气道炎症、痰内毒素、气道高反应、特异反应性和肺功能。根据喘息和哮喘史识别哮喘患者。研究数据显示,NEA患者(痰液嗜酸粒细胞<2.

JAMA Pediatr:儿童早期接触动物可降低其哮喘的发生风险

JAMA Pediatr:儿童早期接触动物可降低其哮喘的发生风险早期接触动物和儿童哮喘发生之间的关系并未明确,既往关于此方面的研究得出了相互矛盾的结果。本研究旨在确定早期暴露于狗与农场动物中是否会增加儿童日后哮喘发生的风险。采用队列研究方法,共纳入了2001年1月1日到2010年12月31日之间出生的1011051名瑞典儿童,以评估早期接触狗和农场动物与哮喘发生风险之间的关系。查阅记录狗和农场登记

Lancet Respir Med:哮喘研究的四大领域—呼吸病学2015年度总结专题

胎儿发育期饮食调节是预防哮喘和其他复杂疾病的关键,应用系统生物学的方法分析多元数据对于充分了解哮喘进展的生物化学过程是完全有必要的。

BMJ:对鸡蛋过敏的年轻人使用流感减毒活疫苗是安全的

此开放性的、IV期干预性研究共纳入了779名对鸡蛋过敏的年轻人(2-18岁)。该队列中270名研究对象存在鸡蛋过敏史,其中157名出现过呼吸和/或心血管症状。445名曾被诊断为哮喘或喘息。接种疫苗后至少观察30分钟后才可允许研究对象离开,72小时后进行电话随访。

JAMA:择期剖宫产儿童的不良健康结局

全球范围内分娩方式的选择上“择期剖宫产”无疑占了较大比例,一些地区择期和急诊剖宫产发生率接近50%!先前有观察性研究表明,剖宫产生产的后代在儿童时期更容易生病,但是这些观察性研究并没有对关键的混杂因素进行校正。此外并没有关于择期剖宫产分娩的后代,新生儿期以后的死亡风险报道。因此研究者进行了一项研究,拟探究择期剖宫产与后代健康问题或儿童期死亡风险的关系。该研究在1993-2007年间共纳入了321 

Baidu
map
Baidu
map
Baidu
map